A. G. X. Zeng

The paper constructs a reference atlas of human hematopoiesis and maps AML differentiation patterns, revealing genetic and non-genetic factors driving aberrant differentiation in leukemia.

This study uses scRNA-seq to analyze B-ALL samples, revealing transcriptional heterogeneity and developmental origins, with specific subtypes associated with distinct cell populations and clinical outcomes.

This study identifies how DNMT3A and TET2 mutations in hematopoietic stem cells confer a selective advantage by reducing inflammation and aging effects.

The paper identifies a human HSC subset with inflammatory memory that accumulates with age and clonal hematopoiesis, potentially increasing cancer and infection risks.

This study shows that KDM6A loss in AML increases sensitivity to PARP and BCL2 inhibitors, suggesting a new combination therapy approach for KDM6A-mutant AML.

This study identifies a cellular hierarchy framework in AML that links disease heterogeneity with drug response and develops a 7-gene biomarker predictive of drug sensitivity.

This study shows that lysosomes are regulated by TFEB and MYC to balance catabolic and anabolic processes in hematopoietic stem cells, influencing their fate and activation.